Core Viewpoint - The company has received a medical device registration certificate for its new generation folic acid testing kit, which enhances its competitiveness in the anemia detection market [1] Group 1: Product Development - The company announced the receipt of a registration certificate from the Guangdong Provincial Drug Administration for the folic acid testing kit, classified as a Class II medical device [1] - The product is designed for the quantitative measurement of folic acid levels in human serum or plasma samples, aiding in the diagnosis of megaloblastic anemia [1] - The new testing kit utilizes a sandwich chemiluminescence immunoassay method, improving sensitivity and precision [1] Group 2: Market Position - The company and its subsidiaries have obtained 106 registration certificates for chemiluminescence detection reagents, enhancing the testing menu for its chemiluminescence project [1] - This expansion is expected to strengthen the company's market competitiveness in the immunodiagnostics field [1] Group 3: Future Outlook - The actual sales performance of the product post-launch will depend on future market promotion efforts, and the specific impact on the company's future performance remains unpredictable [1]

Core Viewpoint - The company has received a medical device registration certificate for its new product, a folic acid assay kit, which enhances its market competitiveness in the anemia detection field [1] Group 1: Product Development - The company has obtained the registration certificate from the Guangdong Provincial Drug Administration for the folic acid assay kit, classified as a Class II medical device, with a registration number valid until December 18, 2030 [1] - The folic acid assay kit is designed for the quantitative measurement of folic acid levels in human serum or plasma, aiding in the diagnosis of megaloblastic anemia [1] - This new generation product utilizes a sandwich chemiluminescent immunoassay method, improving the sensitivity and precision of the assay [1] Group 2: Market Position - The company and its subsidiaries have secured a total of 106 registration certificates for chemiluminescent assay kits, further enriching its testing menu in the immunodiagnostic field [1] - The advancements in product offerings are expected to enhance the company's competitiveness in the immunodiagnostic market [1] Group 3: Sales and Market Impact - The actual sales performance of the newly launched product will depend on future market promotion efforts, and the specific impact on the company's future performance remains unpredictable [1]

证券日报网讯 12月23日，普门科技发布公告称，公司于2025年12月23日召开职工代表大会，选举刘敏 女士担任公司第三届董事会职工代表董事。 ...

（文章来源：证券日报） 证券日报网讯 12月23日，普门科技在互动平台回答投资者提问时表示，截至2025年9月30日，公司普通 股股东总数为11859户。 ...

公司于2025年12月23日召开职工代表大会，选举刘敏女士担任公司第三届董事会职工代表董事，任期自 本次职工代表大会选举通过之日起至公司第三届董事会任期届满之日止。 格隆汇12月23日丨普门科技(688389.SH)公布，公司董事会于近日收到非独立董事李大巍先生递交的书 面辞职报告。因公司治理结构调整，李大巍先生申请辞去公司第三届董事会非独立董事职务，辞任后， 李大巍先生仍然担任公司副总经理。 ...

深圳普门科技股份有限公司 关于非独立董事离任暨选举职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：688389 证券简称：普门科技 公告编号：2025-086 深圳普门科技股份有限公司（以下简称"公司"）董事会于近日收到非独立 董事李大巍先生递交的书面辞职报告。因公司治理结构调整，李大巍先生申请辞 去公司第三届董事会非独立董事职务，辞任后，李大巍先生仍然担任公司副总经 理。 公司于 2025 年 12 月 23 日召开职工代表大会，选举刘敏女士担任公司第三 届董事会职工代表董事，任期自本次职工代表大会选举通过之日起至公司第三届 董事会任期届满之日止。 一、董事离任情况 (一) 提前离任的基本情况 | 是否继续 | 是否存在 | 在上市公 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 原定任期 | 具体职务 | 未履行完 | 姓名 | 离任职务 | 离任时 ...

（文章来源：证券日报） 证券日报网讯 12月19日，普门科技在互动平台回答投资者提问时表示，公司积极拥抱AI技术革新，一 方面致力于将先进的智能解决方案融入到产品和服务中，为临床提供更加精准、高效的产品解决方案； 另一方面将利用AI平台赋能公司各系统的运营，提升公司经营效率。公司将视实际业务开展情况考虑 是否与相关企业开展合作。 ...

证券日报网讯12月19日，普门科技在互动平台回答投资者提问时表示，2025年9月，安徽和县"体外诊断 试剂产业化项目"已奠基，目前建设工作正在顺利推进中。 ...

Core Viewpoint - The company emphasizes its platform-based development model, which allows for diversification across multiple products and markets, enhancing resilience against market uncertainties [1] Group 1: Company Strategy - The management team possesses extensive experience in platform-based company management, aligning with industry development characteristics and long-term strategic planning [1] - The company is expanding in four major business segments: in vitro diagnostics, clinical medicine, dermatology and aesthetics, and consumer health, leveraging 17 years of technological accumulation and channel resource development [1] Group 2: Competitive Advantage - The multi-product and multi-market approach creates a unique competitive advantage, supporting the company's potential for sustained and stable growth in the long term [1]

普门科技（688389.SH）12月19日在投资者互动平台表示，H100Plus是公司糖化血红蛋白分析仪系列中 的高端机型，可以实现45s快速检测，是国产品牌中血红蛋白变异体识别速度最快的仪器，产品性能优 越，目前已在国内多家三甲医院装机。公司已经实现了糖化血红蛋白检测高、中、低端的全系列布局， 可以满足包括基层医院在内的不同客户群检测需求。 （记者 王晓波） 每经AI快讯，有投资者在投资者互动平台提问：国家将糖化血红蛋白检测纳入老年人免费筛查，而公 司H100Plus分析仪专用于定量检测人全血中的糖化血红蛋白（HbA1c）含量，为糖尿病的诊断、监测和 管理提供精准支持，该产品已通过美国NGSP和国际IFCC双重认证，性能达到国际同类产品水平，请问 是否已成功进入高端医院市场？未来在基层市场的拓展计划是什么？ ...